**Core Concept**
The management of psoriatic arthritis involves the use of disease-modifying antirheumatic drugs (DMARDs) to control both joint and skin symptoms. **Psoriatic arthritis** is a type of arthritis that occurs in people with **psoriasis**, characterized by joint inflammation and skin lesions. The goal of treatment is to reduce inflammation and prevent joint damage.

**Why the Correct Answer is Right**
The correct answer is often a **TNF-alpha inhibitor** or another biologic agent, as these have been shown to be effective in treating both the joint and skin manifestations of psoriatic arthritis. **Methotrexate** is also commonly used, especially in mild cases. However, the most effective treatment, particularly in severe cases or when conventional therapies fail, involves biologic agents.

**Why Each Wrong Option is Incorrect**
**Option A:** Without knowing the specific option, it's hard to comment, but if it's not a biologic agent or **methotrexate**, it might not be the first choice.
**Option B:** Similarly, if this option does not align with current guidelines for psoriatic arthritis treatment, it would be incorrect.
**Option C:** If this option suggests a non-biologic, non-DMARD treatment, it might not be the preferred choice for managing psoriatic arthritis.

**Why Each Wrong Option is Incorrect** cannot be completed without knowing the specific options.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that treatment of psoriatic arthritis often requires a multidisciplinary approach, including dermatology and rheumatology input. **TNF-alpha inhibitors** have significantly improved outcomes for patients with psoriatic arthritis.

**Correct Answer:** Unfortunately, the correct answer choice is not provided to give a specific response. Normally it would be **Correct Answer: [Letter]. [Answer Text]**, for example, **Correct Answer: D. Methotrexate or a TNF-alpha inhibitor.**